Natco Pharma Ltd (NATCOPHARM) is currently trading at 819.95 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Natco Pharma is a vertically integrated, R&D-led pharmaceutical company that develops, manufactures and markets complex finished dosage formulations (FDF) and APIs, with a strong presence in oncology and specialty generics across the US, India and multiple emerging markets; the company also invests in NCEs, cell and gene therapies to build a biotech pipeline alongside its generic business. Q3 FY26 consolidated revenue was INR 705.4 crore with EBITDA of INR 216.8 crore and a 30.7% EBITDA margin; Q3 PAT was INR 151.3 crore and 9MFY26 PAT stands around INR 1,149.5 crore, showing NATCO Pharma has stabilized earnings despite loss of prior Revlimid tailwinds and is guiding full‑year revenue roughly around INR 4,200–4,300 crore. Natco’s export formulations are the revenue engine, contributing nearly 60% for the quarter and 75.7% for 9MFY26, supported by strong performance from subsidiaries in Brazil, Canada, Middle East and newly acquired exposure through Adcock Ingram; this geographic diversification materially reduces single-product concentration risk and strengthens recurring revenue streams. The company has a deep pipeline of complex ANDAs and Para‑IV opportunities in the US (30 Para IVs with >20 FTFs and 14 approvals), active semaglutide (Ozempic/Wegovy) filings for India and regulated markets, and an explicit M&A playbook targeting large acquisitions to scale international branded businesses and expand NATCO Pharma’s footprint and product mix. NATCO Pharma has committed to biotech investments including eGenesis, NRC-2694 (Phase II approved), Cellogen, Eyestem and Stero Therapeutics, reflecting a dual strategy of near-term generics revenue plus high-risk, high-reward R&D investments that could materially change long-term growth trajectory if clinical programs succeed.

Over the past 52 weeks, Natco Pharma Ltd has traded between a low of ₹789.30 and a high of ₹1,226.10. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Natco Pharma Ltd has a market capitalization of approximately 14,599.25. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Natco Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 14.40 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 14,599.25 Cr, Natco Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Natco Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Natco Pharma Ltd is 14.40. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Natco Pharma’s board approved a rights issue of equity shares to existing shareholders to raise up to ₹1,300 crore.

The current share price of Natco Pharma is stated as ₹830.25.

Natco Pharma disclosed a demand of ₹4,92,25,923, which includes the overcharge amount, penalty, and interest.

Natco Pharma reported consolidated net profit of about ₹206.5 crore to ₹207 crore for Q1 FY27, down 57% year-on-year from about ₹480.3 crore to ₹481 crore.